An embodiment of the present invention provides a method for preparing hydrogenated bisphenol A, comprising: (a) heating a reactor in which bisphenol A, a solvent, and a ruthenium supported catalyst are added; (b) supplying hydrogen into the reactor to react; and (c) blocking the supply of hydrogen to react.

Cannabidiol (CBD) formulation comprising a mixture of full spectrum cannabidiol oil (FSO) and cannabidiol isolate (CBD isolate) is disclosed. The formulation contains a total amount of CBD derived from a combination of an amount of CBD in the FSO and an amount of CBD from the CBD isolate. The formulation of FSO and CBD isolate in used for medicinal and health benefits in a wide range of products, such as tinctures, capsules, creams or lotions, bath salts or bombs, soaps, pet or animal tinctures, and pet or animal edible chews.

The present disclosure provides a novel biphenyl derivative compound or a pharmaceutically acceptable salt thereof. The biphenyl derivative compound or pharmaceutically acceptable salt thereof according to the present disclosure is a compound that increases Nm23-H1/NDPK activity and can inhibit cancer metastasis and growth. Thus, it exhibits excellent effects not only on the prevention, alleviation and treatment of cancer, but also on the suppression of cancer metastasis.

The present disclosure provides a novel biphenyl derivative compound or a pharmaceutically acceptable salt thereof. The biphenyl derivative compound or pharmaceutically acceptable salt thereof according to the present disclosure is a compound that increases Nm23-H1/NDPK activity and can inhibit cancer metastasis and growth. Thus, it exhibits excellent effects not only on the prevention, alleviation and treatment of cancer, but also on the suppression of cancer metastasis.

A method is provided for fabricating a diol containing a bis-cycloaliphate. The diol is hydrogenated with hydrogen and a catalyst. Therein, the diol has a bis-aromatic. The catalyst comprises an active metal and a catalyst carrier. The active metal is a VIII-B-group transition element. The catalyst carrier is an oxide of IV-B-group element. Thus, the diol containing the bis-cycloaliphate is generated.

A method is provided for fabricating a diol containing a bis-cycloaliphate. The diol is hydrogenated with hydrogen and a catalyst. Therein, the diol has a bis-aromatic. The catalyst comprises an active metal and a catalyst carrier. The active metal is a VIII-B-group transition element. The catalyst carrier is an oxide of IV-B-group element. Thus, the diol containing the bis-cycloaliphate is generated.

Provided is a method for preparing 2-cyclohexyl cyclohexanol, including: hydrogenating a cyclohexanone dimer with hydrogen gas at a temperature ranging from 150 to 250 C. in a reactor containing a catalyst to prepare 2-cyclohexylcyclohexanol, wherein the molar ratio of the hydrogen gas and oil ranges from 1 to 25. The method has advantages of high yield properties and allows for mass production, thereby enhancing the value of the industrial application.

Provided is a method for preparing 2-cyclohexyl cyclohexanol, including: hydrogenating a cyclohexanone dimer with hydrogen gas at a temperature ranging from 150 to 250 C. in a reactor containing a catalyst to prepare 2-cyclohexylcyclohexanol, wherein the molar ratio of the hydrogen gas and oil ranges from 1 to 25. The method has advantages of high yield properties and allows for mass production, thereby enhancing the value of the industrial application.

Disclosed are methods of purifying the compound (22E)-(24R)-2-methylene-22-dehydro-1,24,25-trihydroxy-19-nor-vitamin D.sub.3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving (22E)-(24R)-2-methylene-22-dehydro-1,24,25-trihydroxy-19-nor-vitamin D.sub.3 in a solvent comprising ethyl acetate and hexane to form a solution, allowing crystals of (22E)-(24R)-2-methylene-22-dehydro-1,24,25-trihydroxy-19-nor-vitamin D.sub.3 to form and precipitate from the solution, and recovering the crystals of (22E)-(24R)-2-methylene-22-dehydro-1,24,25-trihydroxy-19-nor-vitamin D.sub.3 from the solution.

Disclosed are methods of purifying the compound (22E)-(24R)-2-methylene-22-dehydro-1,24,25-trihydroxy-19-nor-vitamin D.sub.3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving (22E)-(24R)-2-methylene-22-dehydro-1,24,25-trihydroxy-19-nor-vitamin D.sub.3 in a solvent comprising ethyl acetate and hexane to form a solution, allowing crystals of (22E)-(24R)-2-methylene-22-dehydro-1,24,25-trihydroxy-19-nor-vitamin D.sub.3 to form and precipitate from the solution, and recovering the crystals of (22E)-(24R)-2-methylene-22-dehydro-1,24,25-trihydroxy-19-nor-vitamin D.sub.3 from the solution.